Skip to content
HowShorted

OCULAR THERAPEUTIX, INC short interest in 2023

In 2023, OCULAR THERAPEUTIX, INC's disclosed short interest ran from 3.66% of shares outstanding on 13 Jan 2023 to 5.52% on 29 Dec 2023, a change of +1.86 percentage points. The year's high was 8.77% on 30 Jun 2023 and its low 3.66% on 13 Jan 2023, averaging 6.17% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 10.06 days on 14 Jul 2023. Full history: OCULAR THERAPEUTIX, INC.

Cite this page
Plain
Wikipedia
BibTeX

By year: 2018 · 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026

Aggregate net short position time series for OCULAR THERAPEUTIX, INC in 2023

2023 in figures

Start of year
3.66% (13 Jan 2023)
End of year
5.52% (29 Dec 2023)
Change
+1.86 pp
High
8.77% (30 Jun 2023)
Low
3.66% (13 Jan 2023)
Average
6.17%
Highest days to cover
10.06 (14 Jul 2023)
SEC filings marked
9

Every report in 2023

OCULAR THERAPEUTIX, INC short interest in 2023
SettlementShort interestDays to coverFilings since previous
13 Jan 20233.66%4.03results (8-K)
31 Jan 20233.81%5.16
15 Feb 20234.07%1.00
28 Feb 20235.17%2.63
15 Mar 20235.78%3.6710-K filed, results (8-K)
31 Mar 20235.93%6.33
14 Apr 20235.51%6.68
28 Apr 20236.25%3.96
15 May 20237.13%5.6510-Q filed, results (8-K)
31 May 20238.58%6.11
15 Jun 20238.41%3.07
30 Jun 20238.77%4.22
14 Jul 20238.67%10.06
31 Jul 20237.96%8.45
15 Aug 20236.20%5.0310-Q filed, results (8-K)
31 Aug 20235.18%5.53
15 Sep 20235.24%7.69
29 Sep 20235.15%7.03
13 Oct 20235.48%5.90
31 Oct 20236.00%7.73
15 Nov 20237.32%3.8710-Q filed, results (8-K)
30 Nov 20236.65%6.80
15 Dec 20235.72%2.28
29 Dec 20235.52%2.88

See also: OCULAR THERAPEUTIX, INC's full history · most shorted US stocks of 2023 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.